Key facts
- It has raised $40.4M; the latest was Later Stage VC ($11.4M) in Jan 2026.
- Notable investors include Green Pine Capital Partners, 5Y Capital, Sky9 Capital, MassBio, Blue Ocean Capital Group — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Signet Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Signet Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Signet Therapeutics
Developer of life science reagents and diagnostic solutions designed to support biomedical research and clinical testing accuracy. The company offers advanced molecular biology kits, immunoassay reagents, and customizable assay development services, thereby helping researchers, laboratories, and hospitals achieve reliable experimental outcomes and diagnostic insights, enabling scalable scientific breakthroughs and patient-centered healthcare solutions.
- Sector
- Healthcare
- HQ
- Shenzhen, China
- Founded
- 2020
- Website
- signettx.com/
- Ownership
- Privately Held (backing)
Signet Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Signet Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Signet Therapeutics in its N-PORT filings yet. We sweep new filings monthly.